Wedbush initiates HEMAB outperform
Wedbush initiates coverage of Hemab Therapeutics with an outperform rating, citing potential growth prospects. This may impact investor sentiment on the stock.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.